Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
2000 participants
OBSERVATIONAL
2017-01-01
2021-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Platelet Indices in Patients Undergoing Primary PCI and Its Prognostic Value
NCT04290949
The Prognosis of Patients After PCI：a Multi-center Study in China
NCT05614050
Prognostic Implications of Physiologic Investigation After Revascularization With Stent
NCT04684043
PRospective Evaluation of Complete Revascularization in Patients With multiveSsel Disease Excluding chroNic Total Occlusions
NCT05230446
Risk Factors Promoting Coronary Plaque Progression In China
NCT02692014
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PMI
No interventions assigned to this group
non-PMI
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients permit informed consents
Exclusion Criteria
* NYHA class III-IV heart failure
* moderate-to-severe valvular disease
* missing post-PCI troponin results
* active infection, respiratory failure
* liver dysfunction (liver enzyme \>3xURL or bilirubin \>2xURL),
* malignancy and systemic connective tissue disease
* unable to get a informed consents
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Zhongshan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
180 Fenglin Road
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PMI-CAD-PCI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.